Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened

• On April 14, 2026, Corbus Pharmaceuticals Holdings, Inc. announced via Form 8-K and press release that the last patient has been enrolled and completed the first clinical visit ("Last Patient First Visit") in the CANYON‑1 Phase 1b clinical trial of CRB‑913 for the treatment of obesity. The company says the study is on track for completion in summer 2026.

Key Details

• Study: CANYON‑1 Phase 1b; 16-week, double‑blind, placebo‑controlled, dose‑ranging trial.
• Enrollment/Population: 240 obese, non‑diabetic participants across multiple U.S. sites.
• Dosing cohorts: placebo and CRB‑913 at 20 mg, 40 mg, and 60 mg once daily (QD); all active participants start at 20 mg/day with titration to cohort dose.
• Treatment schedule: participants dosed for 3 months and monitored for an additional month post‑dosing.
• Drug: CRB‑913 described as a once‑daily, highly peripherally restricted oral CB1 inverse agonist.
• Corporate filing: announcement furnished as Exhibit 99.1 to the Form 8‑K (filed April 14, 2026); report signed by CEO Yuval Cohen.

Why It Matters

• Completion of enrollment and the last patient first visit is a key operational milestone that keeps the CANYON‑1 study on schedule for a planned summer 2026 completion, reducing enrollment risk and supporting the company’s timeline for upcoming data.
• This is an early‑stage (Phase 1b) study; the filing does not include clinical results or financial impacts. Investors should view this as a development milestone rather than proof of efficacy or safety outcomes.